Shanghai Kaibao Pharmaceutical Co Ltd

Chart & Performance

D1W1MN

P/E

17.94

P/S

4.57

EPS

0.36

Div Yield, %

1.55%

Shrs. gr., 5y

—

Rev. gr., 5y

0.75%

Revenues

1.47b

-7.57%

Net income

376m

+14.55%

CFO

279m

-27.10%

Dividend

Jun 19, 20240.1 CNY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern Chinese medicines primarily in China. Its primary products include Tanreqing injection for the treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infection; Tanreqing capsules that clears heat and detoxifies and removes phlegm; tiopronin for injection, which improves liver function of various acute and chronic hepatitis; Tiopronin enteric-coated tablets for adjuvant treatment of chronic hepatitis; and Xiongdan dropping pills that clears heat, calms liver, and improves eyesight. The company was founded in 2000 and is based in Shanghai, China.

URL

http://www.xykb.com/

IPO date

Jan 08, 2010

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT